Brukinsa

one prior therapy, Mantle Cell Lymphoma, Waldenstrom Macroglobulinemia + 3 more
Treatment
20 Active Studies for Brukinsa

What is Brukinsa

ZanubrutinibThe Generic name of this drug
Treatment SummaryZanubrutinib is a medication used to treat mantle cell lymphoma and other types of cancer. It works by blocking an enzyme called Bruton’s tyrosine kinase (BTK), which is involved in the survival and proliferation of malignant B cells. Compared to the first-generation BTK inhibitor ibrutinib, zanubrutinib is more selective and has fewer side effects. The FDA approved zanubrutinib in November 2019 based on clinical trial results showing that it could help reduce tumors in 84% of patients with mantle cell lymphoma. In 2021, the
Brukinsais the brand name
image of different drug pills on a surface
Brukinsa Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Brukinsa
Zanubrutinib
2019
1

Effectiveness

How Brukinsa Affects PatientsZanubrutinib is a drug that stops certain cancer cells from growing and spreading. It works by blocking an enzyme called BTK, which helps the cancer cells survive. Taking Zanubrutinib can reduce the size of tumors caused by mantle cell lymphoma.
How Brukinsa works in the bodyZanubrutinib works by blocking Bruton's tyrosine kinase (BTK), an enzyme important to the B-cell receptors on the surface of B cells. When activated, BTK helps B cells to survive, reproduce, and travel to other parts of the body. Zanubrutinib binds to the active site of BTK, preventing it from working properly. This ultimately reduces the size of tumors, inhibits B cell movement, and lowers the expression of certain proteins involved in the immune system.

When to interrupt dosage

The proposed dosage of Brukinsa is contingent upon the determined condition, including one prior therapy, Mantle Cell Lymphoma and rituximab. The quantity of dosage fluctuates, in relation to the technique of delivery (e.g. Capsule - Oral or Capsule, gelatin coated) demonstrated in the table beneath.
Condition
Dosage
Administration
one prior therapy
, 80.0 mg
Capsule, gelatin coated, Oral, Capsule, gelatin coated - Oral, , Capsule - Oral, Capsule
Mantle Cell Lymphoma
, 80.0 mg
Capsule, gelatin coated, Oral, Capsule, gelatin coated - Oral, , Capsule - Oral, Capsule
Waldenstrom Macroglobulinemia
, 80.0 mg
Capsule, gelatin coated, Oral, Capsule, gelatin coated - Oral, , Capsule - Oral, Capsule
Relapsed Marginal Zone Lymphoma
, 80.0 mg
Capsule, gelatin coated, Oral, Capsule, gelatin coated - Oral, , Capsule - Oral, Capsule
Lymphoma
, 80.0 mg
Capsule, gelatin coated, Oral, Capsule, gelatin coated - Oral, , Capsule - Oral, Capsule
rituximab
, 80.0 mg
Capsule, gelatin coated, Oral, Capsule, gelatin coated - Oral, , Capsule - Oral, Capsule

Warnings

There are 1 known major drug interactions with Brukinsa.
Common Brukinsa Drug Interactions
Drug Name
Risk Level
Description
Tucatinib
Moderate
The metabolism of Tucatinib can be decreased when combined with Zanubrutinib.
Brukinsa Toxicity & Overdose RiskThere is not much information available about zanubrutinib overdose.
image of a doctor in a lab doing drug, clinical research

Brukinsa Novel Uses: Which Conditions Have a Clinical Trial Featuring Brukinsa?

At present, 113 active clinical trials are investigating the potential of Brukinsa to ameliorate Mantle Cell Lymphoma, in combination with Rituximab, and one prior therapy.
Condition
Clinical Trials
Trial Phases
Mantle Cell Lymphoma
97 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Phase 1, Early Phase 1
Relapsed Marginal Zone Lymphoma
0 Actively Recruiting
Waldenstrom Macroglobulinemia
8 Actively Recruiting
Phase 2, Phase 1
rituximab
0 Actively Recruiting
Lymphoma
11 Actively Recruiting
Phase 1, Phase 2
one prior therapy
0 Actively Recruiting

Brukinsa Reviews: What are patients saying about Brukinsa?

1Patient Review
12/10/2021
Brukinsa for Waldenstrom's Macroglobulinemia
Disabling
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about brukinsa

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does Brukinsa treat?

"BRUKINSA protects your healthy cells from a protein that is overproduced in Waldenström's macroglobulinemia and mantle cell lymphoma."

Answered by AI

Who manufactures Brukinsa?

"The agreement between Catalent and AbbVie will allow Catalent to manufacture BRUKINSA™, a Bruton's tyrosine kinase (BTK) inhibitor that has recently been approved by the United States Food and Drug Administration (FDA) as a treatment for mantle cell lymphoma (MCL) in adult patients who have received at least one previous therapy."

Answered by AI

Is Brukinsa a chemo drug?

"Zanubrutinib (Brukinsa®) is a chemotherapy regimen that is used to treat lymphoma, specifically mantle cell lymphoma. It is a targeted therapy that works by inhibiting Bruton’s tyrosine kinase (BTK), which is a protein that is essential for the growth and survival of B cells. This medication is given as a pill that is taken orally (by mouth). The usual starting dose is 100 mg taken twice daily. The dose may be increased or decreased based on the person’s response to the medication and side effects. The most common side effects of zanubrutinib include fatigue, muscle aches, diarrhea, bruising, and low blood counts."

Answered by AI

How long does Brukinsa take to work?

"At around 7 months into treatment, 92.2% of people taking Brukinsa saw a reduction in cancer cells."

Answered by AI

Clinical Trials for Brukinsa

Have you considered Brukinsa clinical trials? We made a collection of clinical trials featuring Brukinsa, we think they might fit your search criteria.
Have you considered Brukinsa clinical trials? We made a collection of clinical trials featuring Brukinsa, we think they might fit your search criteria.
Have you considered Brukinsa clinical trials? We made a collection of clinical trials featuring Brukinsa, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top